Biotechnology - Dermatologicals

Filter

Current filters:

Dermatologicals

Popular Filters

Positive Ph III results with oral Otezla in skin, nail and scalp of patients with plaque psoriasis

24-03-2014

US biotech firm Celgene has released positive new research findings on Otezla (apremilast), an oral,…

apremilastBiotechnologyCelgeneDermatologicalsOtezlaResearch

US FDA clears Xolair for chronic idiopathic urticaria

23-03-2014

Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

30-01-2014

Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen…

BiotechnologyDermatologicalsJanssen BiotechMarkets & MarketingStelara InjectionUSA

Galapagos in deal with Biogen Idec for scleroderma research

Galapagos in deal with Biogen Idec for scleroderma research

13-11-2013

Belgian biotech firm Galapagos says that a subsidiary has signed a three-year collaboration agreement…

Biogen IdecBiotechnologyDermatologicalsGalapagosLicensingResearch

Rigel sees clear forward path for fostamatinib but will drop R333

25-10-2013

Clinical-stage US drug developer Rigel Pharmaceuticals has announced mixed updates on two of its pipeline…

BiotechnologyDermatologicalsfostamatinibImmunologicalsR333RegulationResearchRigel Pharmaceuticals

NovaBiotics enters co-development agreement for Novexatin

28-08-2013

Scotland-headquartered clinical-stage biotech firm NovaBiotics has entered into an exclusive agreement…

BiotechnologyDermatologicalsLicensingNovaBioticsNovexatinTaro Pharmaceuticals

Actelion bid for Ceptaris looks secured as FDA approves Valchlor

26-08-2013

Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

First in class novel biologic for psoriasis launched in India

13-08-2013

Bangalore, India-based Biocon (BSE: 532523), Asia's premier biotechnology company, has launched its 'first…

ALZUMAbAsia-PacificBioconBiotechnologyDermatologicalsitolizumabMarkets & Marketing

Swedish Pergamum reports positive preliminary efficacy results of LL-37 in chronic leg ulcers

05-07-2013

Pergamum, a portfolio company of Sweden-based investment company Karolinska Development, says that the…

BiotechnologyDermatologicalsKarolinska DevelopmentResearch

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

AAD conference briefs: Celgene's apremilast; and Sanofi's dupilumab

04-03-2013

The European subsidiary of US biotech firm Celgene Corp (Nasdaq: CELG) presented the results from ESTEEM…

apremilastBiotechnologyCelgeneDermatologicalsdupilumabPharmaceuticalRegeneronResearchSanofi

LEO Pharma and 4SC Discovery link for skin disease research

26-02-2013

Privately-held Danish dermatology specialist LEO Pharma has entered into an exclusive research and license…

4SC DiscoveryBiotechnologyDermatologicalsLEO PharmaLicensingPharmaceuticalResearch

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

PharmaEssentia gets certain Asian rights to Kinex' dermatology candidate KX01

03-12-2012

USA-based privately-held Kinex Pharmaceuticals has entered a licensing agreement granting Taiwan's PharmaEssentia…

Asia-PacificBiotechnologyDermatologicalsKinex PharmaceuticalsKX01LicensingPharmaEssentia

RegeneRx explores strategic options

02-02-2012

US biotech firm RegeneRx Biopharmaceuticals. (OTC Bulletin Board: RGRX) revealed yesterday that it has…

BiotechnologyCardio-vascularDermatologicalsLicensingNeurologicalOphthalmicsRegeneRx

LEO Pharma in over $300 million deal for psoriasis therapy

10-01-2012

Privately-held Danish drugmaker LEO Pharma A/S has signed a multi-million dollar in-licensing deal with…

BiotechnologyDermatologicalsLEO PharmaLicensingPharmaceuticalVirobay

Company Spotlight

ImmunoGen

ImmunoGen

Back to top